Objective. To compare the screening performance of the Psoriasis Epidemiology Screening Tool (PEST), Psoriatic Arthritis Screening and Evaluation (PASE) and Early Arthritis for Psoriatic Patients (EARP) questionnaires for detecting PsA among psoriasis patients in a primary care setting.
Introduction
PsA is an inflammatory joint disease, associated with psoriasis [1] . Increasing evidence suggests that diagnosing PsA early and subsequently providing early treatment improves patients' outcomes substantially [25] . Since in the majority of cases the skin symptoms precede the musculoskeletal symptoms, an opportunity for screening arises [6] . Physicians who treat patients with psoriasis, like general practitioners (GPs) and dermatologists, should pay attention to these musculoskeletal symptoms, as timely referral to a rheumatologist can assure early diagnosis and adequate treatment.
To enhance early recognition by dermatologists and GPs several screening questionnaires were developed, such as the Psoriasis Epidemiology Screening Tool (PEST), Psoriatic Arthritis Screening and Evaluation (PASE) and Early Arthritis for Psoriatic Patients (EARP) [79] . These were mostly developed in secondary care and until now four different validation studies have been published, also mostly in secondary care [1013] . However, in many western countries, including the Netherlands, the majority of patients remain under care of their GP. Screening in a primary care setting may therefore be very useful.
The primary objective of this study was to compare the screening performance of the validated PEST, PASE and EARP questionnaires in detecting PsA among primary care psoriasis patients.
Methods

Patients
Between June 2013 and March 2014 a large cross-sectional study in primary care was performed. Ninety-seven GPs from the greater Rotterdam area were willing to participate, with an average patient population of 1600 patients aged 18 years and over per GP. Participating GPs selected their psoriasis patients aged 18 years and over using International Classification of Primary Care code S91 for psoriasis [14] . The International Classification of Primary Care is widely used for coding signs and symptoms in primary care in the Netherlands. All identified psoriasis patients received an invitation from their GP asking them to participate in our study. If patients were willing to participate they were called by a trained interviewer to verify the ever presence of musculoskeletal complaints (joints, tendons or lower back). The interviewer also verified whether they had a diagnosis of psoriasis and sufficient knowledge of the Dutch language to complete the questionnaires. For the purpose of screening we only included patients who were at risk for the target disorder (PsA), so patients with an established diagnosis of PsA were excluded. All patients fulfilling the inclusion criteria during the telephone interview were invited for clinical evaluation. Ethics approval from the Dutch Medical Ethical Committee (M121275) was obtained as well as written informed consent from all participating patients for this study. Detailed information on methodology and inclusion is provided in our recently published paper [15] .
Data collection
Screening tools
Patients were asked to complete a set of questionnaires just before clinical evaluation. Three screening questionnaires were completed: PEST [8] , PASE [7] and EARP [9] . In brief, PEST consists of five yes/no questions and was developed in the UK in a primary care setting. It is considered positive if three or more questions are answered positively. In addition, a manikin is included on which patients can tick off stiff, swollen or painful joints [8] . It has been validated multiple times in secondary care and its sensitivity ranges from 0.28 to 0.77 while its specificity ranges from 0.37 to 0.98 [1013] .
PASE was developed in the USA and consists of 15 questions with a 5-point answer scale (from strongly disagree to strongly agree). The cut-off was set at 47 in the development, but in the first validation by the same group a cut-off value of 44 provided better sensitivity and specificity [7, 16] . This questionnaire has been validated in different studies and for its developmental cut-off of 47 the sensitivity ranges from 0.24 to 0.75 and the specificity from 0.39 to 0.94 [3, 10, 13] . Looking at the cut-off of 44, the sensitivity increases towards 0.760.91, whereas the specificity remains in the same range with 0.410.67 [9, 13] .
EARP is one of the more recently developed screening tools and was developed in Italy in 2012. It consists of 10 yes/no questions with a cut-off value of 3 or higher to be considered positive [9] . This questionnaire has not been validated yet.
The PEST and PASE questionnaire were available in Dutch translation, while the EARP was translated by the research team before the start of the study. The full versions of the screening tools can be found in their respective published papers [79] .
Clinical evaluation
All patients who reported musculoskeletal complaints during the telephone interview were clinically evaluated by a trained research assistant, blinded for the outcomes of the questionnaires. A detailed history was completed, focusing on psoriasis, musculoskeletal complaints and other factors like family history and comorbidities. Physical examination focused on the skin, nails, joints and entheses. Psoriasis severity was assessed by the PASI score. The nails were visually inspected and in case of abnormalities a photograph was taken that later on was evaluated for the presence of nail psoriasis by a dermatologist. The joints were evaluated for tenderness and swelling using the 66/68 joint count. For the evaluation of the entheses, the Leeds Enthesitis Index and Maastricht AS Enthesitis scores were used. These scores are based on tenderness upon manual palpation. If clinical evaluation resulted in at least one tender enthesis, patients were referred for an ultrasonographic examination by an independent trained examiner using Esaote Mylab60 (probe LA 435). US enthesitis was defined as the presence of power Doppler (PD) signal (<2 mm of the bony cortex) or in case of the plantar fascia an increased thickness of the enthesis (>4.4 mm) as a PD signal could not be obtained at the plantar fascia
Case definition
The diagnosis of PsA was based on the CASPAR criteria [17] , where patients must have inflammatory articular disease in the joints, spine or entheses. On top of this, at least three out of the following six points are required: the presence of psoriasis [current (2 points) or history], presence of psoriatic nail dystrophy, absence of RF, dactylitis (diagnosed by a rheumatologist) and radiographic evidence of juxtaarticular new bone formation. The presence of peripheral arthritis and axial disease were confirmed by a rheumatologist. Since there is no commonly accepted clinical definition for enthesitis, we decided to use a combination of clinical characteristics and positive PD signal at the enthesis (<2 mm of the bony cortex).
Statistical analysis
Descriptive statistics were used to describe the patient characteristics. Sensitivity and specificity were calculated using the diagti command in STATA 14 (StataCorp, College Station, TX, USA).
Results
Study participants
For this analysis we had 473 psoriasis patients with musculoskeletal complaints at risk for PsA available. The mean (S.D.) age of the 473 evaluated patients was 55.7 (13.9) years and 51.0% were male (Table 1) . Mean (S.D.) psoriasis duration was 20.7 (16.2) years, with 73.2% of the psoriasis diagnoses confirmed by a dermatologist. The remaining 26.9% of psoriasis cases were confirmed by the GP. At clinical evaluation 71 patients (15.0%) had nail abnormalities consistent with psoriatic nail dystrophy. Median PASI score in the study population was 2.3 (IQR: 14).
Performance of screening tools
Fifty-three out of 473 patients fulfilled our case definition of inflammatory joint disease for which we evaluated the three screening tools. The PEST questionnaire was completed by all 473 patients. The sensitivity was 0.68 (95% CI: 0.54, 0.80) and the specificity was 0.71 (95% CI: 0.67, 0.76). The PASE questionnaire was completed by 461 patients; 12 patients did not complete this questionnaire. For the original cut-off value of 47, the sensitivity was 0.59 (95% CI: 0.44, 0.72) and the specificity 0.66 (95% CI: 0.61, 0.71). When using the cut-off value of 44, the sensitivity increased towards 0.66 (95% CI: 0.52, 0.79) whereas the specificity dropped to 0.57 (95% CI: 0.52, 0.62). The EARP questionnaire was complete by 465 patients; eight patients did not complete this questionnaire. The sensitivity was 0.87 (95% CI: 0.75, 0.95) and the specificity 0.34 (95% CI: 0.30, 0.39) ( Table 2 ).
The sensitivity and specificity were calculated separately for enthesitis and axial or peripheral manifestations of PsA. These results were very similar and can be found in Supplementary File S1, available at Rheumatology Online. When only selecting patients without systemic therapy for their psoriasis (five MTX, four ciclosporin, four etanercept and five adalumimab), the sensitivity increased slightly with 0.02 while the specificity remained more or less the same (see Supplementary File S1, available at Rheumatology Online).
With regard to false negatives, that is, the patients with PsA who are missed when using these screening tools, 60% of axial manifestations were missed by the PEST (Table 3) . For peripheral arthritis only 16.7% was missed by the PEST, while for enthesitis 33.3% of the cases were missed. For the PASE one-third of the peripheral arthritis was missed, independent of the cut-off value, while 36.1 and 44.4% of enthesitis was missed when using the cutoff values of, respectively, 44 and 47. Axial manifestations were missed in 20% when using the cut-off value of 44 and in 40% when using the cut-off value of 47. EARP missed 16.7% of the peripheral arthritis, 11.1% of the enthesitis and 20% of axial manifestations.
Influence of prevalence
Improving early recognition of PsA in primary and secondary care is challenging. Given the different performance of the screening tools, the question of which would be best in clinical practice is often asked. To answer this one has to consider the performance of the tools but also the harm and benefit of the decision after screening and the prior probability of having the disease. Interpreting these factors together creates relevant information to make an informed decision whether or not to implement a certain screening tool in primary care or dermatological care. The ideal scenario for the performance would be to have perfect sensitivity and specificity so both patients and non-patients receive optimal care. Unfortunately, perfect tests are often not available in practice, so one has to trade off sensitivity against specificity or vice versa. The choice in this trade-off directly relates to the subsequent clinical decision, in our case referral to the rheumatologist. One could argue that the EARP would be the best screening tool to use, because of its high sensitivity (0.87), where only a few patients would be missed. However, when choosing the EARP, this would also result in about 70% false-positive patients because of the low specificity. This becomes especially relevant if the prior probability, here the prevalence of psoriasis and the prevalence of PsA, is low. If the prevalence of PsA is low, say 3/100 patients as found in our primary care sample [15] , 70% of the 97 non-PsA patients will be identified as potential PsA and referred to the rheumatologist. This means that the rheumatologist will have to see 26 psoriasis patients in order to find one patient with PsA, maybe not the best way to use scarce outpatient clinic time. We believe the PEST fits the trade-off between sensitivity and specificity best, although this still means that a rheumatologist has to see 15 patients to find one true PsA as the prevalence we found was 3.2% (increasing towards 7.0%, depending on how we dealt with the non-responders) [15] . If the prevalence of PsA is moderate, say 30/100 patients in dermatological care, the same test will lead to 20 detected PsA cases and 20 false-positive cases. In this case one in every two referred patients actually has PsA. A graph of the influence of various prevalences on the posterior probability of having PsA when using different tests can be found in Supplementary File S2, available at Rheumatology Online.
Discussion
In this large primary care based study among psoriasis patients we validated three of the existing screening questionnaires for PsA. The PEST had the best performance with a sensitivity of 0.68 (i.e. 68% of the PsA cases were identified) and a specificity of 0.71 (i.e. 29% were falsely identified as PsA). The PASE performed slightly worse with a sensitivity of 0.59 for the cut-off of 47 and 0.66 for the cut-off of 44. The specificity for the PASE cut-off of 47 was 0.66 and 0.57 for the cut-off of 44. The EARP has not been validated before and while the sensitivity we found (0.87) is comparable to the sensitivity in the development study (0.85), the specificity was considerably lower with 0.34 (vs 0.92 in the development study) [9] .
As we did one of the first validations in primary care, it is interesting to put this in perspective with studies that have validated the tools in secondary care. Three out of four studies showed sensitivity of 0.630.91 [10, 12, 13] , while one study among psoriasis patients with and without musculoskeletal pain resulted in sensitivity of 0.240.28 [11] . Specificity varied from 0.37 to 0.80 in the same three studies while 0.940.98 was found in the other study. Why these strong differences occurred is unclear, but it may have to do with patient selection and/or case definition. Recently, the CONTEST group developed a new screening tool based on the best performing items of several individual screening tools for PsA using data from secondary care [18] . Recently it was validated and compared with the PEST in a primary care setting. Compared with our study, they found slightly lower sensitivity and specificity for the PEST in their cohort. With a prevalence of PsA in the range of 37%, implementing a screening tool for all psoriasis patients seems a big effort to identify approximately one PsA patient per GP at a given moment. Another option could be to screen patients only if they suffer from musculoskeletal complaints. The prevalence of PsA increased in our study towards 9.8%, which would lead to approximately three PsA patients per practice. Adding the PEST in this situation would increase the probability of having PsA after a positive PEST screening tool towards 20% (see Supplementary File S2, available at Rheumatology Online).
Besides implementing a screening tool, raising awareness among both patients with psoriasis and GPs could also aid early recognition. On the one hand, one could think about making patients themselves more aware of their risk for developing PsA; this could be achieved by setting up campaigns involving, for example, psoriasis patients organisations. One could also think about educating GPs by local rheumatologists; this seems to be an effective way to enhance adequate referral from primary to secondary care for early referral of any inflammatory arthritis including PsA [19] .
Certain strengths and limitations should be taken into account when interpreting the results of this study. One of the strengths of our study is that it is one of the first validations of the screening tools in primary care. Most developments (except PEST) and validations have been performed in secondary care. Secondly, our study is the first validation of the EARP questionnaire and we have a fairly large and complete database of psoriasis patients at risk for PsA. With regard to limitations, we only included patients with musculoskeletal complaints in this study. This implies that the specificity figures we found are probably an underestimation if interpreted for a cross section of the psoriasis patient spectrum.
In conclusion, in our primary care based study the PEST questionnaire had the most favourable trade-off between sensitivity and specificity to screen for PsA. However, as the prevalence of both psoriasis and PsA was fairly low in our primary care setting, screening only patients suffering from musculoskeletal complaints instead of all patients with psoriasis would likely be a better allocation of resources.
